Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Call Transcript
2025-05-06 23:13:47 ET
Rigel Pharmaceuticals, Inc. (RIGL)
Q1 2025 Earnings Conference Call
May 06, 2025, 04:30 PM ET
Company Participants
Ray Furey - Executive Vice President, General Counsel & Corporate Secretary.
Raul Rodriguez - President & Chief Executive Officer
Dave Santos - Chief Commercial Officer
Lisa Rojkjaer - Chief Medical Officer
Dean Schorno - Chief Financial Officer
Conference Call Participants
Kalpit Patel - B. Riley Securities
Joe Pantginis - H.C. Wainwright
Farzin Haque - Jefferies
Presentation
Operator
Greetings, and welcome to Rigel Pharmaceuticals Financial Conference Call for the First Quarter 2025. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce our first speaker, Ray Furey, Rigel's Executive Vice President, General Counsel and Corporate Secretary. Thank you, Mr. Fury. You may begin.
Ray Furey
Welcome to our first quarter 2025 financial results and business update conference call. The financial press release for the first quarter 2025 was issued a short while ago and can be viewed along with the slides for this presentation in the News and Events section of our Investor Relations site on rigel.com. As a reminder, during today's call, we may make forward-looking statements regarding our financial outlook and our plans and timing for regulatory and product development. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent annual report on Form 10-K for the year ended December 31, 2024, and subsequent filings with the SEC, including our quarter one quarterly report on Form 10-Q on file with the SEC. Any forward-looking statements are made only as of today's date, and we undertake no obligation to update these forward-looking statements to reflect subsequent events or circumstances.
At this time, I would like to turn the call over to our President and Chief Executive Officer, Raul Rodriguez. Raul?
Raul Rodriguez
Thank you, Ray, and thank you, everyone, for joining today. Also with us today are Dave Santos, our Chief Commercial Officer; Lisa Rojkjaer, our Chief Medical Officer; and Dean Schorno, our Chief Financial Officer....
Read the full article on Seeking Alpha
For further details see:
Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Call TranscriptNASDAQ: RIGL
RIGL Trading
-3.13% G/L:
$26.0825 Last:
96,605 Volume:
$26.87 Open:



